Prostate Cancer

Neugene antisense targets are effective in preclinical prostate cancer models

Published in Gene Therapy Weekly, December 18th, 2003

AVI BioPharma, Inc., (AVII) announced publication of two preclinical studies evaluating the potential of AVI's Neugene antisense compounds in prostate cancer models.

Since target selection is of paramount importance in antisense drug development, these studies demonstrate AVI's progress in validating prostate cancer targets. Results were published in the peer-reviewed journals Cancer Gene Therapy and Clinical Cancer Research.

"These two studies demonstrate AVI's commitment to developing antisense drugs for the potential treatment of cancer," said Patrick L. Iversen, senior vice president of research and development at AVI. "We are...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2003-12-18)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry